At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET
SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, including the successful $172.5 million IPO in February 2026. The company highlighted positive 12-month Phase 1/2 data for its BIM-IOL System, showing sustained intraocular pressure control and elimination of eye drops in 97% of patients. Despite increasing R&D and G&A expenses, the IPO has extended its cash runway to fund operations through 2028.
- Raised $172.5 million in gross proceeds from IPO completed on February 9, 2026.
- 12-month Phase 1/2 trial data show 98% of patients on the 78-mcg dose of BIM-IOL System were free of IOP-lowering eye drops, with a 34% mean IOP reduction and no serious ocular adverse events.
- Cash, cash equivalents, and short-term investments totaled $107.4 million as of December 31, 2025, with post-IPO cash expected to fund operations through 2028.
- Net loss was $12.6 million for Q4 2025 ($5.72/share), up from $8.4 million ($4.58/share) in Q4 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access